Clinical pathological gene research for the pathophysiology and diagnostic accuracy of pancreatic tumors

Not Applicable

• Conditions: Pancreatic tumor

• Registration Number: JPRN-UMIN000044562
• Lead Sponsor: niversity of Yamanashi Division of gastroenterology and hepatology

Brief Summary

The most common genetic abnormalities obtained were KRAS (82%), TP53 (57%), SMAD4 (19%), and RET (16%). Genetic abnormalities that could be markers for FDA-approved molecular-targeted drugs were found in 30 patients (20%) in 93 locations, and 14% of patients had abnormalities in genes related to homologous recombination repair, a potential marker for FOLFIRINOX, which is used in clinical practice.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-03-31
• Study Start: 2021-06-16
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 172

Inclusion Criteria

Not provided

Exclusion Criteria

not applicable

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Positive rate of genetic markers that relate prognosis.

Secondary Outcome Measures

Name	Time	Method
To identify clinical factors that relate prognosis. Overall gene mutation rate and molecular marker expression rate. Expression rate of gene mutations and molecular markers associated with each clinical factors.